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“BASAL CELL CARCINOMA –  
A PROSPECTIVE CLINICO EPIDEMIOLOGICAL  
& PATHOLOGICAL STUDY” 
 
ABSTRACT 
 
AIMS AND OBJECTIVES:  
 To find out the age and sex incidence of basal cell carcinoma in patients 
attending the outpatient department of dermatology, RGGGH, Chennai. To find 
out the various clinical and histopathological features of basal cell carcinoma. 
 
MATERIALS AND METHODS:  
 This was a prospective observational study carried out at dermatology 
outpatient department, RGGGH, Chennai. Patients with clinical diagnosis of 
basal cell carcinoma were included in the study after thorough history, clinical 
examination, routine and special investigations like skin biopsy. 
 
RESULTS:  
 Out of 20 patients with basal cell carcinoma 6 were males and 14 were 
females with a male to female ratio of 1:2.33. Females (70%) were most 
commonly affected than males (30%). Most commonly affected age group was 
50 – 70 years (70%). Distribution of basal cell carcinoma in our study was 
confined to head and neck area and the most common site involvement was 
nose (30%), followed by periocular region (25%) and cheek (15%). Most 
common morphological subtype encountered in our study was nodular / nodulo-
ulcerative BCC (70%), followed by pigmented type (25%) and superficial BCC 
(5%). The most common histological variant observed in our study was nodular 
type (55%), followed by pigmented variant (25%), adenoid (5%), basisquamous 
(5%), superficial BCC (5%) and BCC with sebaceous differentiation (5%). 
 
CONCLUSION:  
 This study highlights a paradoxically increasing trend of BCC with 
female predilection. 
 Since early age of onset of basal cell carcinoma being reported in persons 
with genetic defect, these patients should be advised for periodic follow- 
up and strict photo protective measures. 
 Early detection and treatment of lesions are crucial to decrease the 
functional and cosmetic morbidity, this study highlights the importance of 
improving awareness among general practitioners, public health workers 
and general population. 
 
KEY WORDS: 
           Basal cell carcinoma, clinical variants, exicision biopsy, histopathology. 
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INTRODUCTION 
  
 The skin is the largest and most complex organ of our body. It has 
an ectodermal cover and it is in continuity with the mesenchymal tissues. 
Tumour represents uncontrolled proliferation of a particular cell type 
which results clinically in different patterns of lesions.  
 
 Basal cell carcinoma is the most common malignant skin tumour 
and the most prevalent cancer type among white-skinned populations 
worldwide and particularly in industrialized Western societies.1 
 
 In addition, the incidence of skin cancers is rising all over the 
world. Geographical location plays an extremely important role in the 
distribution and frequency of incidence rates. In people with outdoor 
occupations like miners, quarry men, railway engine drivers and firemen, 
the frequency of BCC is high.2 
 
 It is a slow-growing malignant tumour of the skin that invades the 
adjacent tissues with a metastatic incidence of 0.01% - 0.028%.3 
 
 Ultraviolet radiation plays a major role in the development of 
BCCs. Radiation exposure, exposure to arsenic salts, chemical 
carcinogens, chronic irritation, chronic inflammation, pre existing skin 
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lesions such as discoid lupus erythematosus, burn scar and vaccination 
scar are the various other causal factors.4 
 
 Immunosuppression also to be suspected a role in the pathogenesis 
of skin cancer. Incidence basal cell carcinoma is high among 
immunosuppressed individuals and the lesions were commonly found on 
trunk and arms as compared to immunocompetant patients. 
 
 Ethnical differences in types of skin, immunological and genetic 
factors also play a role in the development of BCC. 
 
 Head and neck are known as the most common localizations of 
basal cell carcinoma (80%), but the anatomical site distribution is 
different for the histological subtypes. Head and neck is the most 
common site for nodular BCC whereas the trunk is the most common 
location of superficial BCC.5 
 
 Males are most commonly affected than females. A population 
based incidence survey in Australia shows an annual incidence of 849 in 
males and 605 in females per100000 population.6 
 
 BCC generally occurs in adults over 40 years of age but it may 
occur in children and young adults.7 
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              In children it is usually associated with genetic defects such as 
xeroderma pigmentosum, nevus sebaceous, nevoid basal cell syndrome, 
rombo syndrome or bazex syndrome. 
 
Clinical types: 
There are five clinical types basal cell carcinoma known to occur: 
1. Nodular basal cell carcinoma 
2. Micronodular basal cell carcinoma 
3. Superficial basal cell carcinoma 
4. Infiltrating / Morpheic basal cell carcinoma 
5. Fibroepithelioma of pinkus 
  
Syndromes associated with BCC: 
1. Bazex syndrome 
2. Nevoid basal cell carcinoma syndrome 
3. Linear unilateral basal cell nevus 
4. Xeroderma pigmentosum 
5. Rasmussen syndrome 
6. Rombo syndrome 
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From histologic point of view basal cell carcinoma can be divided into 2 
types: 
 Undifferentiated 
 Differentiated 
 
 Those latter group shows some degree of differentiation towards 
the cutaneous appendages of hair, sebaceous glands, apocrine glands or 
eccrine glands. 
 
Undifferentiated BCCs: 
1. Nodular BCC 
2. Micronodular BCC 
3. Pigmented BCC 
4. Superficial BCC 
5. Morpheic BCC 
6. Fibroepithelioma of pinkus 
 
Differentiated BCCs: 
1. Keratotic BCC 
2. Cystic BCC 
3. Adenoid BCC 
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Histologic variants of basal cell carcinoma: 
1. Adamantinoid type 
2. Granular type 
3. Clear cell type 
4. Matricial type 
 
 The aim of this study is to estimate the age and sex-related 
incidence of basal cell carcinoma in our hospital between October 2014 
and September 2015 and to classify basal cell carcinoma subtypes 
according to their location, morphology and histopathological features. 
 
 It is confined to the patients attending the Dermatology 
department, RAJIV GANDHI GOVERNMENT GENERAL HOSPITAL, 
CHENNAI. 
 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
BASAL CELL CARCINOMA 
 
Synonym: Rodent ulcer, Jacob’s ulcer, Basalioma 
 Basal cell carcinoma was first described by Jacob in 1827. 
Krompecher in 1903 discovered that the tumour was arising from the 
basal cells of the epidermis. 
 
 In 1914, Adamson stated that these are nevoid tumours originating 
from latent embryonic foci arised from their dormant state at a later 
period of life, either from embryonic pilosebaceous follicles, or from 
embryonic sweat ducts. Mallory suggested that they are carcinomas of 
hair matrix cells. 
 
 Foot in 1947 reported that they are carcinomas arising from 
distorted primordial adnexal-hair, sebaceous or sweat gland.8 
 
 Wallace and Halpert in 1950, described them as benign tumours of 
the hair matrix, differentiated to the hair follicle and called them 
trachoma.9 
 
 According to Lever they were nevoid tumours or hamartomas 
arising from the primary germ cells. 
  
 7   
 
 
 
DEFINITION: 
 Basal cell carcinoma is the most common malignant tumour of the 
skin that usually arising from basal cells of the epidermis and its 
appendages.10 
 
EPIDEMIOLOGY: 
 Worldwide, white skinned populations have higher incidence of 
basal cell carcinoma and overall the incidence of BCC is in rising trend. 
Its incidence rate varies according to ethnicity and geographical location.1 
 
 Prevalence of this tumour rises within a population as exposure to 
sunlight increases but the distribution of the lesions does not correlate 
with the area of maximum exposure to UV rays.11 
 
 Basal cell carcinomas are commonly seen on sun exposed areas 
especially on head and neck area.5 It may also occurs on the trunk, limbs 
and rarely on palms, soles, mucous membrane & genitals has been 
reported.12 
 
 BCC most frequently affects males than females due to greater 
occupational and recreational exposure to ultraviolet radiation. 
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 Basal cell carcinoma generally occurs in persons older than 40 
years of age but it may occurs in children and young adults. There are 
three rare forms of basal cell carcinoma with early onset. 
 
1. Linear, unilateral basal cell nevus- all lesions are present at birth      
2. Nevoid basal cell syndrome  
3. Bazex syndrome           
 
 In the above last two conditions patients manifest lesions before                  
puberty.13 
 
ETIOLOGY & PATHOGENESIS: 
1. ULTRAVIOLET RADIATION: 
 UVB- induced mutations in the keratinocyte cellular DNA initiates 
tumour formation after a latent period of 20–50 years. 
 
 Absorption of UVB by DNA causes photoproducts formation such 
as cyclopyrimidine dimers and pyrimidine-pyrimidine photoproducts.14 
 
 These photoproducts  cause cytosine–thymidine (C–T) transition. 
This step is followed by due to failure of the repair mechanism, leading to 
dysregulation of gene function and tumour formation. 
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The genes affected by this C–T transition:   
1. ras proto-oncogene- responsible for cell signaling for many growth 
factor receptors. 
2. p53 tumor suppressor gene.15 
3. Drosophila PTCH1 gene- implicated in the nevoid BCC 
syndrome.16 
 
 UVB initiates BCC formation and promotes tumour growth by 
producing  immunosuppression. This is achieved by depletion of 
Langerhans cells that stimulates cytokines like TNF-α and IL-10 and 
suppressing helper T cells with a relative increase in suppressor T cells.17 
 
 Carcinogenic effects of UVA differs from UVB that UVA induces 
oxidation of adenine base leading to the formation of adenine N-1 oxide 
and transversion of thymidine to guanine.18 
 
 Since the UVB dose is high in higher altitude and lower latitude 
risk of BCC increases in those areas.  Intermittent, intense and infrequent 
sun exposure plays an important role in tumour formation in BCC than 
total cumulative dosage of UV radiation.19 Also the teenage period 
exposure and use of artificial tanning devices are increases the risk of 
BCC.20 
 
  
 10   
 
 
 
2. IONIZING RADIATION: 
 BCC may be precipitated by exposure to x-ray and grenz ray.21 
 
3. ARSENIC EXPOSURE: 
 Arsenic exposure in the form of either medicinal, occupational or 
dietary may precipitate the basal cell carcinoma.22 
 
4. IMMUNOSUPPRESSION: 
 There is an association between BCC with HIV infection and organ 
transplant patients.23 
 
 When compared to general population, BCC is 11.5 times more 
common in HIV infected individuals than the general population.24 
 
5. OCCUPATIONAL CAUSES: 
 Occupational exposure to hazardous air pollutants, ionizing 
radiation and burns may precipitate BCC. 
 
 A multicentre European study showed that the frequency of BCCs 
was higher among miners, quarrymen, railway engine drivers and 
firemen.2 
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6. OTHER CAUSES: 
 Occurance of BCC over burn scars 25 and vaccination scars 26 also 
been reported. 
 
 There is evidence of BCC in identical twins has been reported.27 
 
 BCC known to occur in nevus sebaceous and other adnexal 
hamartomas. 
 
7. GENETIC FACTORS: 
 There is an evidence that genetic factors play a role in the 
susceptibility of some individuals to basal cell carcinoma.28 
 
 Mutations in the patched homologue 1 gene (PTCH1), which is 
responsible for the nevoid basal cell carcinoma syndrome and some 
sporadic cases of basal cell carcinoma.16 
 
 PTCH1 gene mutations attributed to 30–40% of sporadic basal cell 
carcinomas.  
 
        Mutations in the PTCH1 gene, the receptor of the sonic hedgehog, 
have downstream effects leading to the accumulation of the transcription 
factor Gli-1, which may play a role in the development of basal cell 
carcinomas.29 
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 A downstream target of the sonic hedgehog pathway SOX9, which 
is  expressed in all basal cell carcinomas as well as in adnexal neoplasms 
of the skin. This suggests a possible contribution of SOX9 to the 
pathogenesis of basal cell carcinomas.28  
 
 BMI-1, a gene belonging to the polycomb group of epigenetic gene 
silencers and which is up-regulated by genes in the sonic hedgehog 
pathway, is overexpressed in basal cell carcinomas.   
 
 Various chemokines may contribute to tumour progression. There 
is also an association with HLA-DR7 and HLA-DR4 in some 
populations.                                    
 
 Mutations in the BAX gene and P53 gene have also been found in 
sporadic cases.30  
 
CLINICAL FEATURES: 
          Basal cell carcinoma most commonly occurs over the head, neck, 
and upper back.  Covered sites involvement including the nipple, penis, 
scrotum, vulva, and perianal region has been reported.31 
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CLINICAL TYPES: 
1. Nodular / Nodulo-ulcerative BCC 
2. Micronodular BCC 
3. Pigmented BCC 
4. Superficial BCC 
5. Morpheaform BCC 
6. Fibroepithelial BCC 
 
1. NODULAR / NODULO-ULCERATIVE BCC: 
 Nodular BCC is the commonest morphological type (60%–80% of 
BCC). It is characterized by a pearly waxy papule(s) with central 
depression, a rolled out or thready translucent border with surface 
changes include erosion or ulceration, bleeding, crusting may be present.  
 
 It slowly ulcerates and infiltrates deeply, causing destruction of the 
eye and nose    and may invade the skull and meninges.  
 
Noduloulcerative basal cell carcinoma, pigmented 
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2. MICRONODULAR BCC: 
 The lesions are flat to raised with poorly defined clinical margins. 
It may have diffuse infiltrative growth pattern that extends beyond the 
clinically apparent margins of the tumour. This type has been associated 
with a higher rate of local recurrence than other types.  
 
 
 
Micronodular basal cell carcinoma 
 
3. PIGMENTED BCC: 
            The morphology of pigmented BCC resembles those of nodular 
type, the only difference is that the pigmented type shows brown 
pigmentation of the lesion due to proliferation of melanocytes in the 
tumour. 
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4. SUPERFICIAL BCC: 
              It forms 10-30% of basal cell carcinomas. It consists of  
erythematous, scaly, slightly infiltrated patches that slowly increase in 
size by peripheral extension. These patches are surrounded by a fine, 
threadlike, pearly border.  
 
 Some small areas of patches usually show superficial ulceration 
and crusting. In addition, their centre may show smooth, atrophic 
scarring.  
 
 In contrast to the first three types of basal cell carcinoma, which 
are commonly situated on the face, superficial BCC mostly occurs on the 
trunk. 
 
 
Superficial basal cell carcinoma 
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5. MORPHEAFORM BCC: 
 This present as a solitary, flat to depressed, scar like, whitish to 
yellowish indurated plaque with indistinct borders. The surface is smooth 
and shiny. The overlying skin remains intact for a long time before 
ulceration finally occurs.  
 
 The term morpheaform arises from a clinical resemblance to 
localized scleroderma or morphea. In this type the tumours, despite being 
deeply infiltrative, may be mistaken clinically for a lesion of morphea or 
for a scar. 
 
 
 
Morpheic type of basal cell carcinoma 
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6. FIBROEPITHELIAL BCC: 
 It manifest as solitary to multiple, sessile to pedunculated, firm 
nodules covered by smooth, slightly reddened skin. Clinically they 
resemble fibromas. The most common location is on the back, especially 
in the lumbosacral region. Prior radiotherapy is a predisposing factor. The 
course of this type is indolent, however invasion may occur. 
 
SYNDROMES ASSOCIATED WITH BCC: 
 There are certain clinical syndromes in which basal cell carcinoma 
occurs more frequently, at an early age and with environmental factors 
either playing a role or facilitating tumour formation. 
 
1. Bazex syndrome: 
 It was first described in 1966.32 It is an autosomal dominant 
inherited condition showing follicular atrophoderma. 
 
 It is characterized by widened follicular openings, like ice pick 
marks, mainly on the extremities and multiple, small, basal cell 
carcinoma on the face. It is common in the childhood, adolescence or 
early adulthood.33 
 
  
 18   
 
 
 In addition, localized anhidrosis, generalized hypohidrosis and 
congenital hypotrichosis on the scalp, as well as in other areas is also 
seen. 
 
2. Nevoid basal cell carcinoma syndrome: 
(Gorlin syndrome) 
 In 1963, Gorlin described this syndrome. It is an autosomal 
dominant condition, characterized by multiple basal cell carcinomas 
occurring all over the body, predominantly over exposed sites and usually 
manifest between 2-35 years of age. 
 
 Started as small nodules and during the “nevoid” stage, there is 
increase in the number and size of the nodules and distributed over the 
face and body. 
 
 During adulthood, many of the BCCs undergo ulceration and in 
later life, the disease enters into a “neoplastic” stage in which some of the 
basal cell carcinomas, especially facial lesions become invasive, 
destructive, and mutilating. 
 
          Occasionally, even death may result from invasion of an orbit and 
of the brain. There also may be metastases to the lung.34 
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 It is associated with milia, epidermal cysts, abnormal ribs, dental 
cysts, characteristic facies and scoliosis, kyphosis, short metacarpals, 
keratosis of palms and soles, supernumery digits, agenesis of corpus 
callosum, dural and periventricular calcification, ovarian fibromata, 
hypogonadism, cataract, mental deficiency, congenital hydrocephalus and 
occasional cerebellar medulloblastomas and calcium deposits in the skin. 
Rarely fibro sarcoma of the mandible35 and ameloblastoma of the lower 
jaw may occur. 
 
 One of the hallmarks of this syndrome is numerous superficial pit 
like depression of the palms and soles 1-3mm in diameter, commonly 
occurring in the 2nd decade of life or afterwards and they represent forme 
frusta of basal cell carcinoma.  
 
3. Linear unilateral basal cell nevus:  
 It is a rare condition, which is characterized by extensive unilateral 
linear or zosteriform eruption, usually present since birth, consisting of 
closely set nodules of basal cell carcinoma.36 The lesions may be 
interspersed with comedones 37 and striae-like areas of atrophy 38. They 
do not increase in size with aging of the patient. 
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4. Xerodermo pigmentosum:  
Definition: 
 Xeroderma pigmentosum (XP) is an autosomal recessive disease 
characterized by photosensitivity, pigmentary changes like 
oculocutaneous pigmentation, premature skin ageing and early neoplasia 
resulting from abnormal DNA repair. Some XP patients have 
neurological complications.10 
 
Pathogenesis: 
 Pathogenesis of xeroderma pigmentosum involves there is defect in 
the nucleotide-excision-repair (NER) pathway, responsible for the 
removal and replacement of damaged DNA.39  
 
 This results in diminished DNA repair in the cells exposed to the 
UVB range of sunlight(290-320nm). This explains the photosensitivity 
and carcinogenesis observed. 
 
Xeroderma pigmentosum and neoplasia:  
 In XP patients, Cultured dermal fibroblasts exhibit increased UV-
induced mutagenesis. This results in neoplasms in XP patients, which 
occur predominantly on sun-exposed surfaces, are thought to be the result 
of UV-induced mutations.40  
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 Even though skin tumours from xeroderma pigmentosum patients 
carry mutations bearing a ‘UV signature’ in the p53 and PTCH genes.41 
UV exposure also triggers a complex series of signal transduction 
pathways that result in immunosuppression of the skin.42 This may also be 
an important factor in patients with XP. 
 
Clinical features: 
 Xeroderma pigmentosum is a multi-system disorder involving the 
skin, eyes, and nervous system.  The patients have poor physical 
development and short stature. The affected children may be normal at 
birth. 
 
 Cutaneous features are persistent erythema, acute sun-burn, xerosis 
and diffuse freckling usually involve photo-exposed body parts by the age 
of 6 months to 3 years. The freckles are varying in colour light to dark 
brown, pinpoint to 1 cm in size, progressive, and permanent. 
 
 Freckles first appear on the face and hands and later on other 
exposed parts, the neck and lower legs, lips and conjunctiva. In severe 
cases the trunk also affected and keratoacanthoma are common in XP. 
 
 There may be associated small, round, white atrophic macules 
giving rise to a mottled appearance. As they progressively increase in 
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number, telangiectases and small angiomas appear interspersed among 
them. 
 
 Most of the cases when manifest in early childhood reach the 
tumour stage before the age of 20 years. Premalignant conditions like 
actinic keratoses and keratoacanthoma are common in XP.  
 
 Basal cell carcinoma may develop as early as in the third or fourth 
year of life in patients with XP. Here BCCs are multiple, mostly of the 
pigmented variety. Other malignancies like squamous cell carcinoma and 
malignant melanoma also common, that may be multiple and co-
occurrence of these tumors may occur. Mutilation of facial features may 
resulting from malignant tumours.  
 
 Ocular manifestations include photophobia, conjunctival xerosis, 
and recurrent conjunctivitis are present in 80% patients with xeroderma 
pigmentosum (XP1) in the initial months of life.  Freckle-like pigmented 
macules gradually appear in the bulbar conjunctiva.  Scarring of the 
eyelids, loss of eyelashes, symblepharon, and ectropion may result from 
acute episodes of photo damage. Other ocular changes include vascular 
pterygium, corneal opacities, ocular keratoacanthoma, and epithelioma of 
the eyelids. 
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 Neurological abnormalities are present in approximately 20% of 
the patients with XP1. These start manifesting in early infancy, up to the 
second decade. The clinical features include mental retardation, 
areflexia/hyporeflexia, spasticity, ataxia, and sensorineural deafness 
occurring in varying combination. 
 
 Neurological involvement is thought to arise from accumulation of 
DNA damage in the absence of adequate nucleotide-excision-repair 
(NER), ultimately leading to neuronal death. 
 
5. Rasmussen syndrome:43 
  It is a syndrome of trichoepithelioma, milia, and cylindromas. 
Autosomal dominant pattern of inheritance. Histopathologically, the 
trichoepitheliomas and milia contained keratinizing cysts with laminated 
centers, peripheral basaloid cells and a thin granular layer. 
 
6. Rombo syndrome:44  
 It is a rare genetic disorder characterized mainly by atrophoderma 
vermiculatum of the face, multiple milia, hypotrichosis, telengiectases, 
acral erythema, trichoepithelioma, basal cell carcinoma and peripheral 
vasodilatation with cyanosis. 
 
 The lesions become visible in late childhood, begins at ages 7 to 10 
years and most pronounced on face. 
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BOILOGIC BEHAVIOUR: 
Local invasion: 
 The dangerous consequences of BCC results from local invasion. 
In general, basal cell carcinoma is a slow-developing malignant tumour 
have an aggressive behaviour with local tissue invasion and destruction.45 
 
 Metastases are rare and it is closely correlate to the size and depth 
of tumour invasion and less so to the histological subtype of the original 
tumor.4 
 
 Although metastases are rare, significant morbidity, such as local 
tissue destruction and disfigurement can occur. There is a case report of 
giant BCC in India, a patient presented with a nonhealing ulcer of the 
face, which is increasing in size for over 20 years. On examination, the 
ulcer covered the entire left side of the face involving the preauricular, 
infraorbital, and bucco mandibular units of the cheek and the orbit and 
resulted in loss of vision.46   
 
Perineural invasion: 
 Perineural invasion (PNI) mostly occurs  in  recurrent and 
histologically aggressive BCCs.47 The presence of PNI has been 
correlated with recurrent lesions, increased duration and size of lesions 
and orbital invasion.48 
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 A study by Niazi and Lamberty observed that PNI in < 0.2% of 
cases and perineural BCC was reported in recurrent tumours with 
preauricular and malar areas in location.49  
 
 Perineural spread in cases of periocular BCCs may results in 
orbital invasion. It may require extensive surgery and exenteration.50  
 
METASTASIS: 
 Metastasis of basal cell carcinoma is rare, with an incidence of 
metastasis ranging  from 0.01% to 0.028%.3 Metastasis to regional lymph 
nodes and lungs is most common.51 Metastasis to the bone and bone 
marrow also been reported.52  
 
Risk factors for metastasis: 
1. Large size of the primary tumour (Giant BCC- >10 cm) 
2. Long standing lesion 
3. Recurrent tumour 
4. Aggressive histological pattern - morpheic, infiltrating and 
micronodular types of BCC 
5. Perineural invasion 
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HISTOPATHOLOGY: 
 The characteristic cell in BCC is the basalioma cell which has a 
large oval or elongated nucleus and relatively little cytoplasm. These cells 
do not reveal any inter-cellular bridges when seen by light microscope. 
The nuclei of the basilioma cells are uniform in size and uniformly 
stained as well.  
 
 The connective tissue stroma is arranged in parallel bundles around 
the tumour masses.The stroma appears mucinous and reacts 
metachromatically. There are retraction clefts seen around the tumour 
masses and lacunae are present due to the absence of the bullous 
pemphigoid antigen.53  
 
 A mild inflammatory infiltrate may be seen, but dense lymphocytic 
infiltrate is usually seen if the lesion clinically shows ulceration. In 
addition, there are variable degrees of cytologic atypia and mitotic 
activity.54 
 
 From the histological point of view basal cell carcinoma divided 
into 2 groups: 
 
1. Undifferentiated 
2. Differentiated 
  
  
 27   
 
 
 
Undifferentiated BCCs: 
1. Nodular BCC 
2. Micronodular BCC 
3. Pigmented BCC 
4. Superficial BCC 
5. Morpheic BCC 
6. Fibroepithelioma of pinkus 
 
Differentiated BCCs: 
1. Keratotic BCC 
2. Cystic BCC 
3. Adenoid BCC 
 
Histologic variants of basal cell carcinoma: 
1. Adamantinoid type 
2. Granular type 
3. Clear cell type 
4. Matricial type 
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Undifferentiated BCCs: 
1. Nodular basal cell carcinoma: 
 It consists of nodules of basaloid cells with a peripheral palisade 
arrangement. Each basaloid cell having a large, oval, and elongated 
nucleus and scanty cytoplasm. The nuclei of basal cells are uniform and 
nonanaplastic and no variation in staining properties or abnormal mitoses.  
 
 Large cystic spaces are formed within the tumour masses due to 
tumour cell degeneration. Retraction artefacts may be present around the 
tumour nodules. In connective tissue stroma the nodules are arranged as 
parallel bundles around the tumour islands and there may be mucinous or 
amyloid deposits. In nodular BCC, the dermal infiltrate is mild to 
moderate, but it becomes dense if ulceration occurs. 
 
Nodular type of basal cell carcinoma 
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2. Micronodular BCC:  
 It consists of small nodules in the upper dermis. It is the least 
common type but it carries high risk of local recurrence. They vary 
between symmetric, circumscribed to asymmetric and infiltrate between 
collagen bundles.  
 
 
Micronodular basal cell carcinoma 
 
 The tumour may infiltrate deeply into the dermis to involve the 
excision margin. Micro-nodular differentiation is seen typically towards 
the base of a tumour. There is an overlap of appearances between 
micronodular and morpheic type of basal cell carcinomas. 
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3. Superficial BCC:  
 There is budding and irregular proliferation of malignant cells 
extends from the basal layer of the epidermis into the dermis.55 The 
islands of tumor mass may attach to the under surface of the epidermis, 
hair follicles or eccrine ducts. The peripheral cell layer of the tumor 
shows palisading. There is only minimal invasion into papillary dermis. 
The tumor islands are surrounded by fibroblasts and there may be 
inflammatory infiltrate in the upper dermis. 
 
 
Superficial basal cell carcinoma. 
 
      The tumor shows buds and irregular proliferation of tumor tissue 
attached to the under surface of the epidermis. 
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4. Pigmented BCC:  
 Histological features of pigmented BCC is resembles with nodular 
BCC. In addition melanin pigment is present within solid islands of basal 
cell carcinoma and in macrophages between the islands of tumor cells. 
Melanocytes are present approximately in 75% of BCCs and melanin 
content of BCC is about 25%. The melanocytes contains plenty of 
melanin granules in their cytoplasm and intermingled between the tumor 
cells. There may be numerous melanophages in the stroma surrounding 
the tumor.56  
 
 
Pigmented basal cell carcinoma 
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5. Fibroepithelioma of pinkus: 
It was first described by Pinkus in 1953.57 In this type long, thin, 
branching, anastomosing strands of basal cell carcinoma are embedded in 
a fibrous stroma. Many of these strands have connections with the surface 
epidermis. There are small groups of dark-staining cells showing 
peripheral palisading along the epithelial strands, like buds on a branch. 
The  tumor is quite superficial and  its lower border is well demarcated.  
Fibroepithelioma can change into an invasive and ulcerating basal cell 
carcinoma.58  
 
 
Fibroepithelioma of pinkus 
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Differentiated BCCs: 
1. Keratotic type-Differentiation towards hair structures 
2. Cystic type-BCC with sebaceous differentiation 
3. Adenoid type- Differentiation towards tubular structures 
 
Keratotic type: 
 This type shows parakeratotic cells and horn cysts in addition to 
the undifferentiated tumour cells. The parakeratotic cells have an 
elongated nuclei and eosinophilic cytoplasm – lie in the strands, 
concentric whorls or around the horn cysts and the latter contain fully 
keratinized cells and represent attempts of hair shaft formation.  
 
Cystic type: 
 This type shows cystic spaces within the tumour lobules. The cyst 
formation is due to necrobiotic changes of tumour cells. The cells in the 
centre show a vesicular appearance suggesting differentiation into 
sebaceous cells.59 
 
Adenoid type: 
 This type shows tubular or glandular like structures. The cells 
arranged in intervening strands resulting in a lace like pattern. The lumina 
are filled with a colloid substance or an amorphous granular material. The 
  
 34   
 
 
degree of differentiation is low that even with histochemistry, it is not 
possible to say whether the differentiation is towards apocrine or eccrine 
glands.60 
 
HISTOLOGICAL VARIANTS OF BCC: 
There are 4 common histological varients of basal cell carcinoma. 
1. Adamantinoid type 
2. Granular type 
3. Clear cell type 
4. Matricial type 
 
Adamantinoid basal cell carcinoma: 
 Adamantinoid BCC shows a histological resemblance to dental 
ameloblastoma or adamantinoma.61 There is solid masses of basaloid cells 
with palisading at the periphery. Inside this layer, the cells have elongated 
nuclei and stellate cytoplasm and it is stretched as thin, connecting 
bridges across empty spaces, as seen in adamantinoma. 
 
Granular BCC: 
 In granular basal cell carcinoma some of the tumor cells have the 
usual basaloid cells appearance, whereas others show a gradual transition 
to granular cells. The granular cells shows  eosinophilic granules with a 
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tendency to coalesce.62,63 These  granule resembles those seen in granular 
cell tumour. 
 
Clear cell basal cell carcinoma: 
 In the clear cell BCC the clear cell pattern may occupy all or part 
of the tumor islands. The clear cells contain vacuoles of varying sizes 
filled with glycogen.64 The vacuoles may cause peripheral displacement 
of the nucleus and giving the cells with signet ring appearance.65 
 
Matricial BCC: 
 In this type there is islands of shadow cells, as seen in 
pilomatricoma, are located within a basal cell carcinoma.66 
 
DIFFERENTIAL DIAGNOSIS: 
Nodular BCC: 
 Dermatofibroma 
 Appentageal tumor 
 Squamous cell carcinoma 
 Dermal nevus 
 
Morpheic BCC: 
 Morphea 
 Scar 
 Trichoepithelioma 
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Pigmented BCC: 
 Compound nevus 
 Lentigo maligna melanoma 
 Nodular melanoma 
 Blue nevus 
 Superficial spreading melanoma 
 
Superficial BCC: 
 Extramammary paget’s disease 
 Superficial spreading melanoma 
 Bowen’s disease 
 Single plaque of eczema 
 Single plaque of psoriasis 
 
Fibroepithelioma of pinkus: 
 Fibroma 
 Skin tag 
 Papillomatous dermal nevus 
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DISEASE STAGING: 
       The staging of basal cell carcinoma is based on TNM classification, 
established by the American Joint Committee of Cancer.67 
 
TNM classification of basal cell carcinoma: 
T - Tumour  
X - Primary cannot be assessed 
T0 - No evidence of primary tumour 
T1 - Tumour <2 cm in size with <2 high risk features 
T2 - Tumour >2 cm in size, tumour of any size with high risk 
features ( >2 mm breshlow thickness, perineural invasion, 
ear as primary site, undifferentiated carcinoma)  
T3 - Tumour with invasion of maxilla,mandible,orbit or 
temporal bone 
T4 - Tumour with invasion of skeleton or perineural invasion 
of skull base 
N - Lymphnode 
X - Lymphnode cannot be assessed 
N0 - No regional lymphnode metastasis 
N1 - Metastasis in a single ipsilateral lymphnode <3 cm in size 
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N2 - Metastasis in a single ipsilaterl lymphnode >3 cm but 
<6cm in size or multiple ipsilaterl lymphnodes <6 cm in 
size or bilateral / contralateral lymphnodes <6 cm in size 
N3 - Metastasis in a lymphnode >6 cm in size 
M - Metastasis 
X - Metastasis cannot be assessed 
M0 - No distant metastasis 
M1 - Distant metastasis 
 
 Patients with a primary cutaneous basal cell carcinoma with or 
without  evidence of regional or distant metastases are divided into the 
following stages: 
 
Stage 1 : Tumor  is 2 cm or less in size, no metastasis 
Stage 2 : Tumor  is more than 2 cm in size, no metastasis 
Stage 3 : Any  size of the tumor with one lymphnode involvement 
measuring 3 cm or less in size or  extension of tumor 
into the maxilla, mandible, orbit or temporal bone 
Stage 4 : Patients with tumor with direct or perineural invasion of 
skull base or those with two or more lymphnodes 
involvement and distant metastasis. 
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TREATMENT: 
 The choice of therapy depends on the site, the size, the number of 
lesions. The success of therapy depends on early recognition, accurate 
histological typing and the method of treatment. The therapy is not 
satisfactory when the basal cell carcinoma involves the orbit, nose or ear. 
 
METHODS OF TREATMENT: 
1. Surgical exicision 
2. Mohs’ micrographic surgery  
3. Cryosurgery with liquid nitrogen. 
4. Radiotherapy  
5. Combination therapy: Surgery + Irradiation of the lesion. 
6. Local cytotoxic therapy 
a. Topical 5% Imiquimod cream 
b. Topical 20% 5-FU ointment 
7. Interferon therapy  
8. Photodynamic therapy  
9. Laser 
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Surgical exicision:  
 Surgical excision has the advantage over nonexcisional techniques 
that histologic confirmation can be made from surgically removed 
specimen.68 
 
 A recent Cohrane review concluded that surgical exicision is the 
best method of treatment for basal cell carcinoma.69 
 
 Conventional surgical excision with predetermined margins based 
on the clinical characteristics of the tumour and provides a specimen for 
histological examination and assessment of the lateral and deep margins 
yielding <2% recurrence rate at 5 years post surgery.70  
 
 Margins of surgical exicision 4 mm were adequate for treating 
nonmorpheaform BCCs < 2 cm in diameter observed by Wolf and 
Zitelli.71 
 
 Chiller et al found that preoperative curatage decrease the positive 
margins and  surgical failure rate of BCC by 24%.72 
 
  
  
 41   
 
 
Disadvantages: 
 Potential for incomplete margin control 
 Standard surgical exicision cure rate is low  as compared to mohs 
micrographic surgery for treating  recurrent basal cell carcinomas, 
morpheic BCCs and high risk anatomical location of tumor.73 
 
Mohs’ micrographic surgery:  
 Mohs’ micrographic surgery is the treatment of choice for high-risk 
primary BCCs, morpheaform, poorly delineated, incompletely 
exicised and recurrent BCCs. 
 It is best method for treating BCCs located on high-risk anatomic 
sites, such as nasolabial fold, periorbital region and postauricular 
sulcus.  
 MMS provides the lowest recurrence rates and it is the first 
treatment of choice for primary facial BCCs with an aggressive 
histopathological subtype.74 
 Mosterd et al also found that treatment with mohs micrographic 
surgery leads to a significantly lower number of recurrences than 
treatment with surgical excision in recurrent facial BCCs.75 
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Curettage and desiccation: 
 Curettage & desiccation is operator-dependent and most frequently 
used treatment modalities for BCC.76 
 For appropriately selected lesions and locations, C&D remains an 
efficacious and cost-effective treatment modality. 
 
Disadvantages: 
 Recurrences were common for lesions located on the nose, temple, 
forehead and ears. 
 It is not recommended for treating morpheic BCC, recurrent BCC 
and large primary BCC. 
 
Cryosurgery: 
 Cryosurgery is a destructive method of treatment that has been 
used for treating basal cell carcinoma. 
 2 freeze-thaw cycles are required for destruction of BCC at a tissue 
temperature of −50°C. 
 To avoid subclinical extension margin of normal tissue also to be 
destroyed. 
 
Disadvantages:  
 Lack of  histological confirmation of tumor removal. 
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 Complications  include post inflammatory hyperpigmentation and 
hypertrophic scar.77 
  Another bad outcome is the fibrous scar tissue may hide the tumor 
recurrence. 
 
TOPICAL TREATMENT: 
1. Topical Imiquimod 
2. Topical 5-FU 
 
Topical imiquimod: 
 FDA approved Imiquimod 5% cream in 2004 for the topical 
treatment of biopsy confirmed, small (less than 2 cm), primary 
superficial BCC. 
 Imiquimod is an immuno modulator acts as Toll-like receptor- 7 
agonist there by induce T helper immunity by stimulating 
interferon-α, tumor necrosis factor-α, and other cytokines . 
 Possible adverse effects include local skin reactions-erythema, 
erosion and crusting. 
 
Topical 5-fluorouracil: 
 5-FU can be  used topically to treat basal cell carcinomas. 
 It should be applied at bed time over the lesion including 1 cm of 
skin surrounding the tumor, 5 days a week for 6 weeks. 
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 Gross et al reported a 90% histologic clearance rate after 3 weeks 
of topical 5-FU treatment.78 
  5-FU is  generally well tolerated with a good cosmetic outcome 
and with only minimal side effects like mild erythema. 
 5-FU is contraindicated in dihydropyrimidine dehydrogenase 
enzyme deficient patients. 
 
Interferon therapy: 
 Interferon α-2b has also been tried in a schedule of 1.5 million 
units injected intralesionally 3 times per week for a period of 3 
weeks. 
 
Photodynamic therapy (PDT): 
 Mechanism of  PDT involves visible light activates 
photosensitizing drug there by producing activated O2 species that 
destroy the cancer cells.  
 Use of photosensitizers like 5-aminolevulinic acid is followed by 
irradiation with  light sources like tungsten filament, xenon arc, 
metal halide, and fluorescent lamps, or lasers like the dye, metal 
vapor, Nd:YAG, light-emitting diode and femtosecond lasers. This 
leads to  mean clearance rates of 87% in superficial BCC and 
53%–71% in nodular BCC with a recurrence rate of 0%–31%.  
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 It is useful for superficial tumors (tumor thickness <3 mm), 
simultaneous treatment of multiple tumors and in 
immunocompromised patients.  
 In extensive BCCs it is used a adjuvant to Mohs micrographic 
surgery. It has the advandage of short healing time and excellent 
cosmetic result. 
 Cure rates for superficial BCCs with Photodynamic therpy is 
around 75% and patients should be monitored closely during the 
first 2–3 years after PDT. 
 
Radiation therapy: 
 It is usefull for a patient unwilling or unable to undergo 
surgery.   
 X-ray therapy may be a very useful modality as adjuvant treatment 
for BCC when margins are positive after excision or for extensive 
perineural or large nerve involvement.79 
 
Disadvantages: 
 Lack of histologic confirmation of tumor removal,  
 Prolonged treatment course 
 Worsening of cosmetic outcome over time like cutaneous atrophy 
and telangiectasia.  
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 It may predispose to aggressive and extensive recurrences. 
 The Cochrane Collaboration found surgery and  radiotherapy to 
appear the most effective treatments for BCC.80 
 
Lasers: 
 Co2, Nd:YAG and photo dynamic lasers can be used to ablate the 
lesion. 
 
COURSE AND PROGNOSIS: 
 Prognosis of BCC is better with appropriate treatment. 
 Mohs’ micrographic surgery yields better control rates as high as 
99%. 
 Monitoring is required for recurrence and development of new 
primary BCCs.  
 Risk of development of new primary BCC is  36% - 50%.81 
 Regular follow up and counselling about photo protective 
measures are required for patients with history of BCC. 
 Frequent monitoring is required for patients with recurrence. 
 About 40%–50% of patients with primary carcinoma will develop 
further BCCs within 5 years. 
 Prognosis is poor for patients with metastasis. 
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Poor prognostic factors: 
1. Tumour size more than 2 cm 
2. Location of the tumour – midfacial distribution 
3. Lesions with ill defined margins 
4. Immunosuppressed patient 
5. Recurrent disease 
6. Histological subtype- morpheic / infiltrative,micronodular 
7. Aggressive histological features- perineural or vascular invasion 
 
BASISQUAMOUS CARCINOMA:  
             Basosquamous carcinoma is an aggressive growth form of BCC. 
It can be confused with squamous cell carcinoma. 
 
             Its histomorphologic classification is controversy  as it shows 
both basal cell and squamous cell carcinoma differentiation in a 
continuous fasion.             
 
             Histologically, it shows infiltrating jagged tongues of tumor cells 
admixed with other areas that shows squamous intercellular bridge 
formation and cytoplasmic keratinization. In contrast to pure BCC, 
basisquamous cells  lacking classic palisading and exibit cytoplasmic 
keratinization.  
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          The transition zone may be present between BCC and SCC. 
          The  risk of local recurrence and metastasis is high with 
basisquamous carcinoma.82 
 
Collision tumor: 
 It is defined as the juxtaposition of two originally separate 
neoplasms and these are sharply demarcated from each other.  
 
 Examples include nevus and basal cell carcinoma, nevus and 
seborrheic keratosis, squamous cell carcinoma and melanoma. 
 
  
Aims & Objectives 
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AIMS & OBJECTIVES 
 
1. To find out the age and sex incidence of basal cell carcinoma in 
patients attending the out-patient department of dermatology, Rajiv 
gandhi government general hospital, Chennai. 
 
2. To find out the various clinical presentations of basal cell 
carcinoma such as morphology, location and size. 
 
3. To find out the histopathological features of the various types. 
  
Materials & Methods 
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MATERIALS AND METHODS 
 
Study design:  
 Prospective observational study 
 
Study period: 
 October 2014 – September 2015 
 
Methodology: 
 Patients who attend the dermatology outpatient department, Rajiv 
Gandhi Government General Hospital with a clinical diagnosis of basal 
cell carcinoma are selected for the study. 
 
 Thorough history related to age, sex, occupation and duration of 
the lesions are noted. Specific and relevant history about the lesion was 
taken, including family history.  History of any medical or surgical 
interventions are noted. 
 
 Thorough clinical examination of the lesions with reference to site, 
number, size, shape, colour, surface, border and consistency are noted. 
 
 Routine investigations like complete blood count, random blood 
sugar, bleeding time, clotting time, HIV 1&2 antibody, VDRL and X-ray 
chest are taken for all the patients.  
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 Using pretested proforma, patient details, clinical findings and 
investigations are recorded. 
 
 Exicision biopsy was done at plastic surgery department. Exicised 
specimen was received for histopathological examination. Sections are 
stained with H&E and studied in both low & high power magnifications. 
 
 Pathologist opinion was obtained. Clinical and histopathological 
correlation was done. 
 
INCLUSION CRITERIA: 
 Patients who attend the dermatology outpatient department with 
clinical diagnosis of basal cell carcinoma.  
 
EXCLUSION CRITERIA:  
 Patients those who are not willing to participate in the study. 
  
Observation & Results 
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RESULTS 
 
SEX DISTRIBUTION OF BASAL CELL CARCINOMA: 
 Total of 20 patients with basal cell carcinoma were included in the 
study. Out of this, 6 patients were males and 14 patients were females. 
 
 Hence in our study basal cell carcinoma was more common in 
females (70%) than males (30%). Male to female distribution was 1: 2.33. 
 
                         Table 1: SEX DISTRIBUTION (N-20): 
MALE FEMALE 
6 14 
 
Figure 1: SEX DISTRIBUTION 
 
 
 
30%
70%
MALE
FEMALE
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AGE DISTRIBUTION OF BCC 
                 Age of the patients ranged from 10-80 years. The most 
commonly affected age group was 51-60 years with 8 (40%) patients, 
closely followed by 61-70 years age group with 6 (30%) patients. 
                Hence in our study Basal cell carcinoma was most common in 
the age group of 51-60 years. 
                
                                Table 2: AGE DISTRIBUTION 
       AGE N-20 
11 – 20 1 
21 – 30 0 
31 – 40 2 
41 – 50 1 
51 – 60 8 
61 – 70 6 
71 – 80 2 
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Figure 2: AGE DISTRIBUTION OF BASAL CELL CARCINOMA 
 
                
            Age distribution of basal cell carcinomas were seen more 
predominantly between 51- 60 years of age with a mean age of 56.7 
years. 
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SEX WISE AGE DISTRIBUTION OF BCC: 
              In the age group of 51-60 years, there were 8 patients with 2 
males and 6 females. It is followed by in the age group 61-70 years there 
were 6 female patients. 
                 
Table 3: SEX WISE AGE DISTRIBUTION OF BCC 
 
 Males are commonly affected in the age group of 31-40 years 
(10%) and 51-60 years (10%).  
 
 In females most commonly affected age group was noted between   
51-60 years (30%) and 61-70 years of age (30%). 
  
Age group Male Female Total Percentage 
11 - 20 1 0 1 5% 
21 - 30 0 0 0 0 
31 - 40 2 0 2 10% 
41 - 50 1 0 1 5% 
51 - 60 2 6 8 40% 
61 - 70 0 6 6 30% 
71 - 80 0 2 2 10% 
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Figure 3: SEX WISE AGE DISTRIBUTION OF BCC 
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DURATION OF THE DISEASE 
         12 cases were noted with duration of lesion between 6 months to 1 
year. It was followed by 3 cases each were noted with less than 6 months 
and more than 2 years duration.   
 
Table 4: DURATION OF THE DISEASE 
Duration of the lesion No-20 
< 6 months 3 
6 months – 1 year 12 
1 – 2 years 3 
>2 years 2 
 
Figure 4: DURATION OF THE DISEASE 
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DISTRIBUTION OF BCC ACCORDING TO SITE 
        Distribution of lesions were confined to head and neck area. The 
most common site of involvement was nose (30%). It was followed by 
periocular area (25%), cheek (15%), forehead (10%), post auricular area 
(10%), upper lip (5%) and chin (5%).   
 
Table 5: DISTRIBUTION OF BCC ACCORDING TO SITE 
Site No- 20 
Nose 6 
Periocular area 5 
Cheek 3 
Forehead 2 
Post auricular area 2 
Upper lip 1 
Chin 1 
 
Figure 5: DISTRIBUTION OF BCC ACCORDING TO SITE 
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SIZE OF THE LESION 
 Most of the lesions  lies between 1- 2 cm (55%) of size. It is 
followed by lesions with >2 cm size (40%) and <1cm in size (5%). 
 
Table 6: SIZE OF THE LESION 
 Size of the lesion No-20 
Less than 1 cm 1 
1 to 2 cm 11 
More than 2 cm 8 
 
Figure 6: SIZE OF THE LESION 
 
 
 
1
11
8
0
2
4
6
8
10
12
< 1 cm 1 - 2 cm > 2 cm
  
 60   
 
 
MORPHOLOGICAL TYPES OF BCC: 
 Most common morphological subtype of BCC was nodular / 
nodulo-ulcerative growth (70%). It was followed by pigmented varient 
(25%) and superficial BCC (5%). 
 
Table 7: MORPHLOGICAL TYPES OF BCC 
Morphology No - 20 Percentage 
Nodular / Nodulo-
ulcerative 14 70% 
Pigmented 5 25% 
Superficial 1 5% 
 
Figure 7: MORPHOLOGICAL TYPES OF BCC 
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HISTOPATHOLOGICAL VARIANTS OF BCC: 
          The most common histopathological variant was Nodular subtype 
(55%) with significant proportion of tumors being pigmented (25%). 
Other subtypes included Basisquamous (5%), Adenoid variant (5%), 
BCC with sebaceous differentiation (5%) and Superficial BCC (5%). 
 
 
Table 8: HISTOPATHOLOGICAL VARIANTS OF BCC 
Histopathological 
variants No – 20 Percentage 
Nodular 11 55% 
Pigmented 5 25% 
Basisquamous 1 5% 
Adenoid 1 5% 
Sebaceous 1 5% 
Superficial 1 5% 
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Figure 8: HISTOPATHOLOGICAL VARIANTS OF BCC 
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CLINICAL PICTURES 
 
Figure (9 ) - Basisquamous carcinoma 
 A 65 year old female with nodulo-ulcerative growth on left cheek, 
histologically confirmed as Basisquamous carcinoma. 
 
 
Figure (10)-Nodular BCC, pigmented variant  
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Figure (11) - Xeroderma pigmentosum 
 
 A 14 year old male patient with freckle like macules and atrophic 
depigmented macules on the sun exposed areas. 
 
 
Figure (12)- Nodulo-ulcerative BCC 
Same patient with nodulo – ulcerative plaque on right side of nose. 
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Figure (13) – Multiple BCC  
 
 A 57 year old male patient with multiple papules and plaques 
present on nose, cheek and periocular region. Some lesions shows surface 
ulceration. 
 
Figure (14) - Superficial BCC 
 
 A 51 year old female patient, clinical picture shows annular plaque 
with beaded margin and surface ulceration. 
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HISTOPATHOLOGICAL PICTURES 
 
 
 
Figure (15)- Nodular basal cell carcinoma shows nodular tumor  
with peripheral palisading. 
 
 
 
Figure (16) – Pigmented BCC 
Melanin pigment is present within solid islands of basal cell carcinoma. 
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Figure (17) – Basal cell carcinoma with sebaceous differentiation. 
 
 
Figure (18) – Sebaceous BCC. High magnification. 
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Figure (19) – Basisquamous carcinoma showing focal keratinization consisting of 
pearls with a colloidal center and an outer row of basaloid cells. 
 
 
Figure (20) – Nodulo-ulcerative BCC shows epidermis with ulceration and 
neoplasm arising from basal layer arranged as clusters. 
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TREATMENT & FOLLOW-UP: 
 
 All the patients were treated by surgical exicision and cosmetic 
reconstruction was done by the plastic surgery department.  
 
 The patients were followed up every 6 months and further follow-
up was also advised.  
Discussion 
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DISCUSSION 
             
 In this study we included total of 20 patients with basal cell 
carcinoma. Among these 6 patients were males and 14 patients were 
females. 
 
Sex distribution: 
 In our study, females were most commonly affected (70%) than 
males (30%) with a male to female ratio of 1: 2.33. 
 
 A study conducted by Laishram et al., ‘pattern of skin 
malignancies in Manipur’ which shows male to female ratio of 1: 2.83 It is 
consistent with our study. 
 
 It is contrast to western studies, a study conducted by Sibel 
hakverdi, retrospective analysis of basal cell carcinoma showed male 
preponderance.84 
 
 BCCs are more common in males as reported in most studies 
worldwide, presumably due to greater occupational exposure to 
ultraviolet radiation (UVR). However, an unusual female preponderance 
was noticed in our study. Indian housewives especially rural women work 
in open kitchen during their household chores and work in the fields 
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during sowing and harvesting seasons exposing them to intermittent, high 
intensity UVR. 
 
 It might explain higher frequency of BCC in females in our study 
as intermittent rather than constant, cumulative UVR exposure is 
implicated in the pathogenesis of BCC. This female predilection may also 
be attributed to structurally thinner skin with lower collagen density in 
the dermis when compared to men. 
 
Age distribution: 
 The most commonly affected age group in our study was 51 – 60 
years (40%), followed by 61 – 70 years (30%) with a mean age of 56.7 
years. 
 
 It is similar to a study conducted by Obaidullah and Aslam which 
showed a mean age of 56.3 years.85 
 
 Maximum age of the patient affected by BCC in our study was 72 
years and the youngest age was 14 years. 
 
 Although basal cell carcinoma is rare in younger individuals, an 
increased incidence has also been noticed in children and young adults.7 
 
 Here we reported a 14 years old male patient with basal cell 
carcinoma and xeroderma pigmentosum. 
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 Xeroderma pigmentosum is a rare autosomal recessive disease 
characterized by photosensitivity, pigmentary changes and early 
neoplasia resulting from abnormal DNA repair. 
 
 Our case presented with diffuse freckling on the face and nodular 
type of basal cell carcinoma on the right side of nose. (Figure -11) 
 
 This patient was treated by means of surgical exicision and 
reconstruction done at plastic surgery department. Also the patient was 
advised strict photo protective measures and regular follow up. 
 
 Higher rates of occurrence of BCC among elderly may be due to 
cumulative UVR induced DNA damage86 as well as reduced efficiency of 
immune-surveillance and DNA repair mechanisms with aging.87 
 
Duration of the disease: 
 Duration of the disease in our study ranging from 4 months to 5 
years. Most of the cases (60%) in our study was reported with 6 months 
to 1 year duration.  
 
 The patients present at a later stage of the disease was attributable 
to lack of awareness about disease entity.  
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 Long duration of the disease may lead to the following 
complications: 
 
 Local invasion may leads to local tissue destruction and 
disfigurement 
 Perineural invasion 
 Metastasis 
 
Distribution of BCC according to site: 
 The distribution of BCC in our study was confined head and neck 
area. 
 
 The most common site of involvement was nose (30%), followed 
by periocular area (25%) and cheek (15%). 
 
 It is similar to a study conducted by Malhotra et al., ‘Basal cell 
carcinoma in the north Indian population’ which showed head and neck 
being the commonest site (91.2%).88 
 
 Another study conducted by Asif et al., showed nose being the 
common site (28.9%) followed by eye (24.7%) and cheek (20.4%) which 
is closely resembles to our study.89 
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Size of the lesion: 
             Size of the lesions in our study ranged from as small as 0.5 cm to 
maximum of 6 cm.  
 
 Risk of metastases  occur when tumor size is > 3 cm in diameter. 
 
Risk of metastases related to tumor size: 
                3 cm – 1 – 2% 
                5 cm – 20 – 25% 
               >10 cm – 50% 
 
 It is also important to know the size of the tumor for TNM staging 
and therapeutic approach. 
 
Morphological types of BCC: 
 The most common morphological sub type of BCC encountered in 
our study was nodular / nodulo-ulcerative type (70%), followed by 
pigmented BCC (25%) and superficial BCC (5%). 
 
 These findings are consistent with a study conducted by 
Sumirkumar et al., ‘A study of basal cell carcinoma in south Asians’ 
which showed common morphological subtype is being nodular / nodulo-
ulcerative BCC (77.8%) and pigmented BCC (22.2%).90 
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 Pain over the lesion was the chief complaint for eight patients and 
it was asymptomatic in twelve patients. Some patients had history of 
bleeding from minor trauma. None of them had any other systemic or 
cutaneous malignancies. There was no significant family history. 
 
Nodular / nodulo-ulcerative BCC: 
 Patients with nodular type of BCC, having cutaneous features of 
skin coloured or hyperpigmented papules, nodules and plaques were 
present on head and neck area most commonly on nose, periocular and 
cheek. Some patients with nodulo-ulcerative lesions shows surface 
changes like ulceration and crusting. 
 
Rare presentations: 
 One 65 year old female patient was present with large nodulo-
ulcerative growth (6×4 cm) on the left cheek of 2 years duration 
and later it was histopathologically diagnosed as basisquamous 
carcinoma. (Figure- 9) 
 Another 57 year old male patient presented with multiple basal 
cell carcinomas as papules, nodules and plaques of varying sizes 
were present on the nose, cheek and preauricular region.  
(Figure-13). 
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Pigmented BCC: 
 Patients with pigmented BCC will be present as nodular lesions 
with grey-black pigmentation. In our study, 5 patients were appears 
clinically pigmented. 
 
Superficial BCC: 
 Superficial BCC usually appear as erythematous, scaly patches that 
slowly increase in size by peripheral extension with fine thread like 
border. 
 
 The patches usually shows superficial ulceration, crusting and 
sometimes with central atrophic scarring.  
 
 Superficial BCC usually occurs on the trunk. But in our study 1 
female patient was present with superficial BCC on forehead.(Figure 14) 
 
Histopathological variants of BCC: 
 The most common histopathological variant in our study was 
nodular type (55%) with a significant proportion of tumors being 
pigmented (25%). Other subtypes included adenoid (5%), basisquamous 
(5%), superficial (5%) and BCC with sebaceous differentiation (5%). 
 
 These findings are closely resembles Malhotra et al., study which 
shows nodular type being the most common histologic variant (64.7%).88 
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 Common histological features of basal cell carcinomas: 
 Basaloid tumor cells 
 Peripheral palisading of lesional cell nuclei 
 Clefting artefact between the epithelium and stroma 
 
Nodular BCC: 
            It was the most common histological subtype observed in our 
study. H &E stained smears showed nodules of basaloid cells with 
peripheral palisade arrangement and peritumoral lacunae were noted in 
all cases. Some cases shows cystic spaces within tumour masses. 
 
Pigmented BCC: 
 It was the second most common histological subtype in our study. 
Histological features are resembles with nodular BCC, in addition there is 
presence of melanin within tumor cells and macrophages were noted in 
pigmented variant. 
 
Superficial BCC: 
 One case presented with superficial BCC with typical features of  
buds and irregular proliferation of tumour tissue attached to the under 
surface of the epidermis.  
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Adenoid BCC: 
 This is the rare histopathological variant of BCC. Here we 
observed one case with Adenoid basal cell carcinoma. In this type tumor 
cells were arranged within clusters and focal lace like pattern of cells 
were made out. 
 
BCC with sebaceous differentiation: 
 It is the another histological variant of BCC, which shows cystic 
spaces within the tumor lobules. Here one case presented clinically as 
nodular type of BCC and histology showed BCC with sebaceous 
differentiation. 
 
Basisquamous carcinoma: 
 In our study we observed one rare case with histological findings 
suggestive of basisquamous carcinoma which was clinically appear as 
nodulo-ulcerative form of BCC. 
 
 Basisquamous carcinoma (BSC) is a rare epithelial neoplasm with 
histological features of both basal cell carcinoma (BCC) and squamous 
cell carcinoma (SCC) and it is linked by a transition zone. It is also 
known as metatypical epitheliomas. 
 
 Most common location of BSC is on the head and neck and mainly 
involving the central face and has a significant male predominance. 
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 In contrast to pure BCC, basaloid cells in basisquamous carcinoma 
have eosinophilic cytoplasm, often with lack of peripheral palisading and 
retraction artifact and may exhibit cytoplasmic keratinization. 
 
 SCC areas are characterized by large polygonal squamoid cells 
with eosinophilic cytoplasm and may reflect cytoplasmic keratinization. 
 
 Like squamous cell carcinoma, basisquamous carcinoma also more  
aggressive and locally invasive . Risk of metastasis is more in BSC than 
forms of BCC.  
 
 Metastatic BSC is difficult to treat and its prognosis is poor. 
 
  
Summary 
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                                    SUMMARY 
 
 In our study out of 20 patients of basal cell carcinoma 6 were males 
and 14 were females. 
 Females were most commonly affected than males. 
 Male to female ratio – 1: 2.33. 
 Most commonly affected age group was 50 – 70 years. 
 Distribution of basal cell carcinoma in our study was confined to head 
and neck area. Most common site of involvement was nose, followed 
by periocular region and cheek. 
 Most common morphological subtype encountered in our study was 
Nodular / nodulo-ulcerative BCC, followed by pigmented variant. 
 Most common histological variant observed in our study was nodular 
type, followed by pigmented variant. 
 
Rare presentations observed in our study: 
 Xeroderma pigmentosum with basal cell carcinoma. 
 Multiple basal cell carcinoma 
 Basisquamous carcinoma 
 Histological variants of BCC includes adenoid and sebaceous 
differentiation. 
  
Conclusion 
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CONCLUSION 
 
 This study highlights a paradoxically increasing trend of BCC with 
female predilection.  
 
 Since early age of onset of basal cell carcinoma being reported in 
persons with genetic defect, these patients should be advised for 
periodic follow up and strict photo protective measures. 
 
 Early detection and treatment of lesions are crucial to decrease 
functional and cosmetic morbidity and costs, this study highlights the 
importance of improving awareness among general practitioners, 
public health workers and general population. 
 
 The clinical and epidemiological data collected in this study would 
serve as a reference for future research and may be helpful in the 
development of preventive and educational strategies.  
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Annexures 
 
 ABBREVIATIONS 
 
1. BCC    – Basal cell carcinoma 
2. SCC    –  Squamous cell carcinoma 
3. BSC    –  Basisquamous carcinoma 
4. UVR    –  Ultraviolet rays 
5. PTCH1 gene  –  Protein patched homolog 1 gene 
6. TNF-α   –  Tumour necrosis factor – α 
7. IL-10   –  Interleukin-10 
8. XP    –  Xeroderma pigmentosum 
9. NER    –  Nucleotide excision repair 
10. PNI    –  Perineural invasion 
11. MMS   –  Mohs’ micrographic surgery 
12. C & D   –  Curettage & Desiccation 
13. 5-FU    –  5-Fluorouracil 
14. PDT    –  Photodynamic therapy 
15. H & E   –  Haematoxylin and Eosin 
  
MASTER CHART 
 
S. 
No Name Age Sex Site 
Clinical 
Type 
Histological 
Type 
1. Suseela 72 F Chin Nodulo-ulcerative Nodular 
2. Punithavathy 61 F Nose Nodular Adenoid 
3. Saroja 65 F Cheek Nodulo-ulcerative Basisquamous 
4. Pappammal 60 F Upper lip Nodulo-ulcerative Nodular 
5. Kamaladevi 65 F Post auricular region Pigmented Pigmented 
6. Nirmalkumar 14 M Nose Nodular Nodular 
7. Mylammal 60 F Cheek Nodular, pigmented Pigmented 
8. Valli 55 F Forehead Nodular Sebaceous 
9. Purusothaman 35 M Post auricular region Pigmented Pigmented 
10. Sekar 57 M Nose,cheek Nodular Nodular 
11. Ayesa bee 66 F Periocular Nodulo-ulcerative Nodular 
12. Kizhiyappan 45 M Nose Pigmented Pigmented 
13. Krishna 72 F Cheek Nodular Nodular 
14. Abdulkathar 60 M Periocular Nodulo-ulcerative Nodular 
15. Rajalakshmi 65 F Nose Nodulo-ulcerative Nodular 
16. Kothandapani 40 M Periocular Nodulo-ulcerative Nodular 
17. Vendavirudham 65 F Periocular Nodulo-ulcerative Pigmented 
18. Indrani 60 F Nose Nodulo-ulcerative Nodular 
19. Prema 51 F Periocular Nodular Nodular 
20. Glory jemima 51 F Forehead Superficial Superficial 
 
S.No – Serial number, M – Male, F – Female  
PROFORMA 
 
Name:      Age:   Sex: M / F 
 
Hospital No.:     Occupation: 
 
Address: 
 
COMPLAINTS 
Skin lesion 
Site 
Duration 
Associated symptoms: Pain / Itching / Altered sensation / Discharge / Colour 
change / Crusting / Bleeding 
Systemic symptoms: 
Past / treatment history: 
Personal / Family history: 
Exposure: Sun / Chemicals / Radiation 
 
GENERAL EXAMINATION   
Built:   
Pallor: Icterus:Fever: 
Other findings: 
PR:   BP: ______ mmHg  Temp:1 
 
SYSTEMIC EXAMINATION  CVS: 
      RS:    
      Abdomen: 
      CNS: 
       
D/E:    Primary lesion 
Macule / Papule / Patch / Nodule / Ulcer / Others 
Site  :    Size  : 
Number :    Shape            :    
Pigmentation :    Colour  : 
Erythema :    Linearity : 
Surface : Flat topped  Elevated  Raised 
   Papillomatous  Smooth  Shiny 
   Verrucous  Fungoid  Indurated 
   Scaling  Crusting  Ulceration 
   Nodular  Telangiectasia 
 
Sessile      :    Pedunculated : 
Dome-shaped   :    Umbilication : 
Borders/margins : Base : 
Warmth  :              Tenderness             : 
Bleeds on touch :      
Consistency  : Soft  /  Cystic  /  Firm  /   Hard 
 
Attachment to underlying structures : 
 
Regional lymph node enlargement : 
 
Any other site with similar lesion : 
Other associated findings  : 
Scalp                               : 
Hair     : 
Oral mucosa    : 
 
INVESTIGATIONS 
 
Blood  CBC  BT  CT  RBS 
 
   HIV 1&2 antibodies  VDRL  
 
X-ray chest 
                       
SKIN BIOPSY   Biopsy No. :    Date: 
Site  : 
Report : 
Therapy        :                                                                 
Follow Up    : 
  
INFORMATION TO PARTICIPANTS 
 
Title :     BASAL CELL CARCINOMA – A PROSPECTIVE  
  CLINICO EPIDEMIOLOGICAL & PATHOLOGICAL STUDY 
 
Principal Investigator :  Dr. AMMASAIGOUNDAN.V  
Co-Investigator(if any) : 
Name of Participant : 
 
Site :   
 You are invited to take part in this study. The information in this document is 
meant to help you decide whether or not to take part. Please feel free to ask if you have 
any queries or concerns. 
 
What is the purpose of research? 
 Basal cell carcinoma is a slow growing malignant tumour of skin. We are 
doing a study to identify the various  morphological and histopathological features of 
basal cell carcinoma. This would help us diagnose and treat these tumours effectively.  
 
 We have obtained permission from the Institutional Ethics Committee.  
 
The study design 
 All the patients presenting to the dermatology OPD of RGGGH, with Basal 
cell carcinoma are included in this study. 
 
Study Procedures 
 The study involves a thorough history and clinical examination. A detailed 
dermatological examination pertaining to the tumour is done. Routine blood 
investigations like Complete haemogram, Random blood sugar are done. 
 
 After the evaluation, the tumours are subjected to incision / excision biopsy  
under local anaesthesia after giving Inj. Xylocaine 2% (local anaesthetic agent) test 
dose and Inj.Tetanus toxoid. The excised specimen is sent for routine 
histopathological examination. This biopsy is a part of the treatment for these skin 
tumours and also provides more information on the type of tumour and aid in  further 
management. You have to review after 1 week for examination of the biopsy site, 
suture removal and collection of the histopatholgy reports.   
 
Possible risks to you –  Biopsy done in the study is a part of the treatment. Some may 
develop allergy to the local anaesthetic agent used for local anaesthesia. It is used 
only after giving test dose. The procedure is done under strict aseptic precautions and 
there is very minimal negligible chances for wound infection. 
 
Possible benefits to you – Excision biopsy done is curative for most of the tumours.  
 
Possible benefits to other people  
The results of the study may provide benefits to the society in terms of advancement 
of medical knowledge and/or therapeutic benefit to future patients.  
 
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, and 
your medical history). By signing this document, you will be allowing the research 
team investigators, other study personnel, sponsors, Institutional Ethics Committee 
and any person or agency required by law like the Drug Controller General of India to 
view your data, if required. 
 
The information from this study, if published in scientific journals or presented at 
scientific meetings, will not reveal your identity. 
 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your medical 
care or your relationship with the investigator or the institution. You will be taken 
care of  and you will not loose any benefits to which you are entitled.  
 
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to 
withdraw from this study at any time during the course of the study without giving 
any reasons. However, it is advisable that you talk to the research team prior to 
stopping the treatment/discontinuing of procedures etc. 
 
 
 
Signature of Investigator                            Signature  of Participant 
Date       Date 
 
 
 
 
 
 
 
 
PATIENT CONSENT FORM 
 
Title of the study :BASAL CELL CARCINOMA – A PROSPECTIVE  
 CLINICO EPIDEMIOLOGICAL &     PATHOLOGICAL STUDY 
 
Name of the Participant: 
 
Name of the Principal(co-investigator): Dr.Ammasaigoundan.V 
 
Name of the Institution:  Department of Dermatology,  
          Rajiv Gandhi  Government General Hospital, Chennai.                                 
 
Documentation of the informed consent 
I ___________________________ have read the information in this form (or it has 
been read for me). I was free to ask any questions and they have been answered. I am 
over 18 years of age and exercising my free power of choice, hereby give my consent 
to be included as a participant in the study (or) I hereby give my consent to include 
my Son / daughter as a participant in this study. 
 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. My rights and responsibilities have been explained to me by the investigator. 
5. I agree to cooperate with the investigator and I will inform him/her immediately if 
I suffer unusual symptoms. 
6. I have not participated in any research study at any time . 
7. I am aware of the fact that I can opt out of the study at any time without having to 
give any reason and this will not affect my future treatment in this hospital. 
8. I hereby give permission to the investigators to release the information obtained 
from me as a result of participation in this study to the sponsors, regulatory 
authorities, Govt. agencies and IEC. I understand that they are publicly presented. 
9. My identity will be kept confidential if my data are publicly presented. 
10. I am aware that if I have any question during this study, I should contact at one of 
the addresses listed above. By signing this consent form I attest that the 
information given in this document has been clearly explained to me and 
apparently understood by me. I will be given a copy of this consent document. 
 
 
Participant’s initials:_______________ 
 
  
 
For adult participants: 
 
Name and signature/thumb impression of the participant (or legal representative if 
participant incompetent) 
 
 
_______________                   _________________          _________________ 
Name                                      Signature                              Date 
 
 
Name and signature of impartial witness (required for illiterate patients): 
 
 
________________               __________________          _________________ 
Name                                    Signature                                  Date 
 
 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
 
 
________________               __________________          ________________ 
Name                                      Signature                                Date 
                                                
 
 
                                          
  
ஆராvசி தகவ தா 
 
பuேகபாளƫக தகவ 
தைல~© 
«tகிய ஆராvசியாளƫ 
¢ைண ஆராvசியாளƫ 
பuேகபாளƫ ெபயƫ 
 
இ|த ஆவ பuேகக தuகைள அைழtகிேறா. இ|த ஆவண{தி  உள 
தகவ நuக பuேகக ேவzமா அல¢ ேவzடாமா என «º எtக 
உதºவதாக அைம­. நuக எ|த ேகவக அல¢ க¯{¢க இ¯|தா 
ேகyக தயuக ேவzடா. 
 
இ|த ஆவ} ேநாtக எ}ன? 
ேதா ©² ேநா ஒ¯ ெபா¢வான ச¯ம ேநா. இ|த ேநாய} பேவ² 
வதuக, உ¯வ மாறuக ம² தி ¤zணய ேவ²பாக 
கzடறிவேத இ|த ஆராvசிய} ேநாtகமா. இ¢ எuக¶t இ|த 
கyகைள திறபட கzடறிய ம² ©² ேநா சிகிvைச தர உதº. 
நாuக இத நி²வன ெநறி«ைறக ¸ அ§மதி ெப²ேளா. 
 
ஆº வவைம~©: 
ெச}ைன ராஜி கா|தி அர ெபா¢ ம¯{¢வமைன ேதா ேநா ©ற 
ேநாயளக பƬºt வ¯ ேதா ©²ேநா உள ேநாயாளக இ|த 
ஆராvசிய ேசƫ{¢tெகாள~பவாƫக. 
 
ஆº நைட«ைறக: 
ஆºt «தலி ஒ¯ «¸ைமயான ேநா வரலா² ம² உட 
பƬேசாதைன ெசய~ப. பற «¸ைமயான ேதா ம² கy 
பƬேசாதைன ெசய~ப. ப} வழtகமான இர{த பƬேசாதைன ெசய~ப. 
மதி~பy ப} ெடyடான ம² ம¯~© ஊசி ெகா{¢ கyக 
கீற / ெவy எt தி ஆºt உyப{த~ப. அகற~பyட கyக 
வழtகமான தி பƬேசாதைனt அ§~ப~ப. இ|த தி பƬேசாதைன இ|த 
ேதா கyக¶t ஒ¯ சிகிvைச நைட«ைறயாகº, ம² கyய} 
வைகைய கzடறிய ஏ¢வாகº உள¢.  ஒ¯ வார கழி{¢ ம² 
பƬசலீைனt ம² ைதய அகற வரேவz. அத} பற தி 
பƬேசாதைன «ºகைள­ ெப²tெகாளலா. 
 
உuக¶t சா{திய«ள இடƫபாக: கy அக² சிகிvைச ம² தி 
பƬேசாதைன இ|த சிகிvைசய} பதிகளா. இதி தாuக¶t ம¯~© 
ம¯|தி ஒவாைம ம² காய{தி ெதா² ஏபட வா~©ள¢. 
இைவ ஏபடாம இ¯tக «}ெனvசƬtைக எ{¢tெகாள~பகிற¢. 
 
உuக¶t சா{திய«ள ந}ைமக: கy தி பƬேசாதைனt 
அகற~பவ¢ பண நt பாuைடய¢. 
 
மற மtக¶t சா{திய«ள ந}ைமக: ஆº «ºக எதிƫகால 
ேநாயாளக¶t ேதா ©²ேநா ம² சிகிvைச றி{த வழி~©ணƫைவ 
மtக¶t ஏப{த உதº. 
 
உuகளட இ¯|¢ ெபற~பyட தகவ இரகசிய{த}ைம: உuக ம¯{¢வ 
தகவக தன­Ƭைம ெதாடƫபான இரகசிய{த}ைம உƬைம உuக¶t 
உz. இ|த ஆவண{தி ைகெய¸{திy, நuக ேதைவயான ஆராvசி 
¸ வசாரைண, மற ஆº பணயாளƫக, வளபரதாரƫக, நி²வன 
ெநறி«ைறக ¸ ம² உuக தரº பாƫைவயட இ|திய ம¯|¢ 
கy~பாy ெஜனர ேபா}ற சyட ேதைவ எ}² ² ஆyக உuகள} 
வவரuகைள ஆராய அ§மதி அளtகிறƫக. இ|த ஆº தகவ, அறிவய 
ப{திƬைககள ெவளயட~பyட அல¢ அறிவய yடuகள 
வழuகினாƫ எ}றா, உuக அைடயாள{ைத ெவள~ப{த மாyேட}. 
 
எ~ப ஆவ பuேகக «யா¢ எ}ற உuக «ைவ அ¢ பாதிt? 
இ|த ஆராvசிய பu ெகாள வ¯~ப இைலெயன§ அ¢ உuகள¢ 
ம¯{¢வ பƬசலீைன ம² சிகிvைசt எ|த ஒ¯ பாதி~© உzடாtகா¢.  
 
இ|த ஆவலி¯|¢ நவ வலகிtெகாள «­மா? இதி பu 
ெகாவ¢ «றி´ உuக வ¯~ப. நவ வலக வ¯பனா 
தாராளமாக வலகிtெகாளலா. என§, அைத நuக சிகிvைசைய 
நி²{தாம /இைடய நி²{¢ «}னƫ  ஆராvசி ¸வட ேபசி 
«ெவtகº எ}² அறிº²{த~பகிற¢. 
 
 
 
 
 
ஆராvசியாளƫ ைகெயா~ப                  பuேகபாளƫ ைகெயா~ப 
 
ேததி                                                  ேததி 
                          
  
ஆராvசி ஒ~©த கத 
 
ஆராvசி தைல~©: ேதா ©²ேநா பறிய ஆராvசி 
 
ெபயƫ:                                         ேததி: 
வய¢:                                         உேநாயாள எz: 
பா:                                          ஆராvசி ேசƫtைக எz: 
 
இட: ேதா ேநா பƬº, ராஜ கா|தி அர ெபா¢ ம¯{¢வமைன. 
 
இ|த ஆராvசிய} வவரuக¶ அத} ேநாtகuக¶ «¸ைமயாக 
எனt ெதளவாக வளtக~பyட¢. 
 
எனt வளtக~பyட வஷயuகைள நா} ©Ƭ|¢ ெகாz நா} 
என¢ சமத{ைத ெதƬவtகிேற}. 
  
எனt வய¢ 18t ேம ஆகிற¢ / 18 வய¢t உyபyட என¢ 
மக}/மக இ|த ஆராvசிய பu ெகாள எனt சமத. 
 
எனt ேதாலி தைச / தி பƬேசாதைன ெச¢ ெகாள சமத. 
 
இ|த ஆரvசிய பறƬ} நிƫ~ப|தமி}றி எ} ெசா|த வ¯~ப{தி} 
ேபƬ தா} பu ெப²கிேற} ம² நா} இ|த ஆராvசியலி¯|¢ 
எ|ேநர« ப}வாuகலா எ}பைத­ அதனா எ|த பாதி~© 
ஏபடா¢ எ}பைத­ நா} ©Ƭ|¢ெகாzேட}. 
 
நா} இ|த ஆராvசிய} வவரuகைள ெகாzட தகவ தாைள~ 
ெப²tெகாzேட}. 
 
நா} எ}§ைடய யநிைனºட} ம² «¸த|திர{¢ட} இ|த 
ம¯{¢வ ஆராvசிய எ}ைன ேசƫ{¢tெகாள சமதிtகிேற}. 
 
எனt ேநாtறியய ¢ைறய ேதா, தைச ம² தி 
பƬேசாதைனt பய}பyட ெம¸tகyகைள ைவ{¢ ஆராvசி 
ம² சிற~© பƬேசாதைன ெச¢ ெகாள சமத ெதƬவtகிேற}. 
 
இ|த ஆராvசிய} «ºகைள ெவளயடலா. அ~ப 
ெவளயyடா, என¢ அைடயாள ரகசியமாக ைவtக~ப எனபத} 
ேபƬ அத சமத ெதறிவtகிேற}. 
 
ஆராvசியாளƫ ைகெயா~ப             பuேகபாளƫ ைகெயா~ப 
  
 
 
 
